New drug ERAS-0015 targets Hard-to-Treat cancers in early trial

NCT ID NCT06983743

Recruiting now Disease control Sponsor: Erasca, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 20 times

Summary

This early-stage study tests a new drug called ERAS-0015 in people with advanced solid tumors that have certain RAS mutations and have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose, either alone or with other drugs. About 200 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Florida Cancer Specalists
RECRUITING

Sarasota, Florida, 34232, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Texas at Tyler
RECRUITING

Tyler, Texas, 75701, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC SOLID TUMORS